Genitourinary cancers are diverse in their presentation, prevalence, and mortality risk. Although there have been significant advancements in medical (eg, immune checkpoint inhibitors and tyrosine kinase inhibitors) and surgical treatments of genitourinary cancers, patients are still at risk for chronic kidney disease, hypertension, and electrolyte derangements in the short and long term. In addition, pre-existing kidney disease may increase the risk of developing some genitourinary cancers. This review focuses on the kidney-related effects of treatments for renal cell carcinoma and bladder and prostate cancers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.semnephrol.2023.151344 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!